{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-390539","form_type":"8-K","ticker":"BNTC","cik":"0001808898","company_name":"Benitec Biopharma Inc.","filed_at":"2026-09-14T20:04:48+00:00","discovered_at":"2026-09-14T20:06:05.571023+00:00","generated_at":"2026-09-14T20:06:38.713707+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Benitec FY2026 net loss $45.5M; BB-301 cohorts complete follow-up, FDA meeting held","bullets":["FY2026 net loss attributable to shareholders was $45.5M ($0.98/share), vs $37.9M ($1.05/share) in FY2025.","Total expenses rose to $51.2M from $41.8M; R&D up to $23.4M, G&A up to $27.8M.","Cash and equivalents $180.0M at June 30, 2026.","All six Cohort 1 low-dose BB-301 patients completed 12-month follow-up; Cohort 2 fully enrolled, all treated safely.","Type C FDA meeting held in 3Q2026 on BB-301 pivotal design; minutes expected in October; pivotal trial init planned mid-2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-390539","json":"https://secwatch.observer/filing/0001193125-26-390539.json","markdown":"https://secwatch.observer/filing/0001193125-26-390539.md","text":"https://secwatch.observer/filing/0001193125-26-390539.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808898/000119312526390539/0001193125-26-390539-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808898/000119312526390539/bntc-20260914.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T20:06:38.713707+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}